{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:02:16Z","timestamp":1762459336820},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s13277-015-4063-1","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T18:43:06Z","timestamp":1441996986000},"page":"7375-7384","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma"],"prefix":"10.1007","volume":"36","author":[{"given":"Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"issue":"4","key":"4063_CR1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","volume":"13","author":"R Ismail-Khan","year":"2006","unstructured":"Ismail-Khan R, Robinson LA, Williams Jr CC, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13(4):255\u201363.","journal-title":"Cancer Control"},{"issue":"9483","key":"4063_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397\u2013408.","journal-title":"Lancet"},{"issue":"5","key":"4063_CR3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1440-1843.2011.01975.x","volume":"16","author":"GV Le","year":"2011","unstructured":"Le GV, Takahashi K, Park EK, et al. Asbestos use and asbestos-related diseases in Asia: past, present and future. Respirology. 2011;16(5):767\u201375.","journal-title":"Respirology"},{"issue":"7","key":"4063_CR4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","volume":"37","author":"PA Zucali","year":"2011","unstructured":"Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev. 2011;37(7):543\u201358.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"4063_CR5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","volume":"30","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4063_CR6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00404-013-3128-x","volume":"289","author":"X Wu","year":"2014","unstructured":"Wu X, Li D, Liu L, et al. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer. Arch Gynecol Obstet. 2014;289(6):1309\u201314.","journal-title":"Arch Gynecol Obstet"},{"key":"4063_CR7","doi-asserted-by":"crossref","first-page":"161954","DOI":"10.1155\/2014\/161954","volume":"2014","author":"\u00d6 Bostanc\u0131","year":"2014","unstructured":"Bostanc\u0131 \u00d6, Kemik \u00d6, Kemik A, et al. Preoperative serum levels of mesothelin in patients with colon cancer. Dis Markers. 2014;2014:161954.","journal-title":"Dis Markers"},{"issue":"2","key":"4063_CR8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.22024","volume":"105","author":"K Baba","year":"2012","unstructured":"Baba K, Ishigami S, Arigami T, et al. Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol. 2012;105(2):195\u20139.","journal-title":"J Surg Oncol"},{"issue":"5","key":"4063_CR9","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","volume":"13","author":"M Ho","year":"2007","unstructured":"Ho M, Bera TK, Willingham MC, et al. Mesothelin expression in human lung cancer. Clin Cancer Res. 2007;13(5):1571\u20135.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4063_CR10","doi-asserted-by":"crossref","first-page":"e114900","DOI":"10.1371\/journal.pone.0114900","volume":"9","author":"G Tozbikian","year":"2014","unstructured":"Tozbikian G, Brogi E, Kadota K, et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One. 2014;9(12):e114900.","journal-title":"PLoS One"},{"issue":"1","key":"4063_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1472-6890-14-35","volume":"14","author":"A Ali","year":"2014","unstructured":"Ali A, Brown V, Denley S, et al. Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clin Pathol. 2014;14(1):35.","journal-title":"BMC Clin Pathol"},{"issue":"10","key":"4063_CR12","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190\u20138.","journal-title":"J Biol Chem"},{"issue":"11","key":"4063_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1440-1827.2006.02024.x","volume":"56","author":"M Maeda","year":"2006","unstructured":"Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int. 2006;56(11):649\u201354.","journal-title":"Pathol Int"},{"issue":"3","key":"4063_CR14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1349-7006.2007.00715.x","volume":"99","author":"C Sapede","year":"2008","unstructured":"Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci. 2008;99(3):590\u20134.","journal-title":"Cancer Sci"},{"issue":"5","key":"4063_CR15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","volume":"15","author":"I Hellstrom","year":"2006","unstructured":"Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006;15(5):1014\u201320.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"4063_CR16","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","volume":"20","author":"TK Bera","year":"2000","unstructured":"Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20(8):2902\u20136.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"4063_CR17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","volume":"13","author":"Z Tang","year":"2013","unstructured":"Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem. 2013;13(2):276\u201380.","journal-title":"Anticancer Agents Med Chem"},{"issue":"9396","key":"4063_CR18","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","volume":"362","author":"BW Robinson","year":"2003","unstructured":"Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612\u20136.","journal-title":"Lancet"},{"issue":"2","key":"4063_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","volume":"12","author":"R Hassan","year":"2006","unstructured":"Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447\u201353.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4063_CR20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","volume":"17","author":"J Creaney","year":"2011","unstructured":"Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2011;17(5):1181\u20139.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4063_CR21","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","volume":"28","author":"P Wheatley-Price","year":"2010","unstructured":"Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010;28(20):3316\u201322.","journal-title":"J Clin Oncol"},{"issue":"17","key":"4063_CR22","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","volume":"13","author":"A Cristaudo","year":"2007","unstructured":"Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13(17):5076\u201381.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4063_CR23","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","volume":"13","author":"BD Grigoriu","year":"2007","unstructured":"Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13(10):2928\u201335.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4063_CR24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","volume":"3","author":"J Schneider","year":"2008","unstructured":"Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3(11):1317\u201324.","journal-title":"J Thorac Oncol"},{"key":"4063_CR25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/1471-2407-14-674","volume":"14","author":"M Linch","year":"2014","unstructured":"Linch M, Gennatas S, Kazikin S, et al. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer. 2014;14:674.","journal-title":"BMC Cancer"},{"issue":"11","key":"4063_CR26","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","volume":"6","author":"K Hollevoet","year":"2011","unstructured":"Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011;6(11):1930\u20137.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4063_CR27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","volume":"141","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet K, Nackaerts K, Thas O, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest. 2012;141(2):477\u201384.","journal-title":"Chest"},{"issue":"10","key":"4063_CR28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","volume":"69","author":"J Creaney","year":"2014","unstructured":"Creaney J, Dick IM, Meniawy TM, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014;69(10):895\u2013902.","journal-title":"Thorax"},{"issue":"10","key":"4063_CR29","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1515\/CCLM.2011.242","volume":"49","author":"S Yamada","year":"2011","unstructured":"Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med. 2011;49(10):1721\u20136.","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"4063_CR30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","volume":"62","author":"J Creaney","year":"2007","unstructured":"Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007;62(7):569\u201376.","journal-title":"Thorax"},{"issue":"2","key":"4063_CR31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0021-9258(17)42180-6","volume":"269","author":"N Yamaguchi","year":"1994","unstructured":"Yamaguchi N, Hattori K, Oh-eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269(2):805\u20138.","journal-title":"J Biol Chem"},{"issue":"9","key":"4063_CR32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1349-7006.2006.00246.x","volume":"97","author":"K Shiomi","year":"2006","unstructured":"Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC\/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006;97(9):928\u201332.","journal-title":"Cancer Sci"},{"issue":"2","key":"4063_CR33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","volume":"35","author":"J Creaney","year":"2013","unstructured":"Creaney J, Sneddon S, Dick IM, et al. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers. 2013;35(2):119\u201327.","journal-title":"Dis Markers"},{"issue":"6","key":"4063_CR34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","volume":"181","author":"K Hollevoet","year":"2010","unstructured":"Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med. 2010;181(6):620\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"4063_CR35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","volume":"353","author":"HI Pass","year":"2005","unstructured":"Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353(15):1564\u201373.","journal-title":"N Engl J Med"},{"issue":"3","key":"4063_CR36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/09031936.00226111","volume":"41","author":"I Pantazopoulos","year":"2013","unstructured":"Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41(3):706\u201315.","journal-title":"Eur Respir J"},{"key":"4063_CR37","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.2741\/3004","volume":"13","author":"MK El-Tanani","year":"2008","unstructured":"El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci. 2008;13:4276\u201384.","journal-title":"Front Biosci"},{"issue":"13","key":"4063_CR38","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/onc.2009.478","volume":"29","author":"K Tajima","year":"2010","unstructured":"Tajima K, Ohashi R, Sekido Y, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010;29(13):1941\u201351.","journal-title":"Oncogene"},{"issue":"6","key":"4063_CR39","first-page":"2205","volume":"29","author":"R Ohashi","year":"2009","unstructured":"Ohashi R, Tajima K, Takahashi F, et al. Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. Anticancer Res. 2009;29(6):2205\u201314.","journal-title":"Anticancer Res"},{"issue":"2","key":"4063_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/CCLM.2010.066","volume":"48","author":"AJ Rai","year":"2010","unstructured":"Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med. 2010;48(2):271\u20138.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"4063_CR41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1309\/TWCQV536WWRNEU51","volume":"130","author":"S Cappia","year":"2008","unstructured":"Cappia S, Righi L, Mirabelli D, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol. 2008;130(1):58\u201364.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"4063_CR42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.exer.2009.09.018","volume":"90","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Marmorstein LY. Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res. 2010;90(3):374\u20135.","journal-title":"Exp Eye Res"},{"issue":"2","key":"4063_CR43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canlet.2012.06.019","volume":"325","author":"AJ Obaya","year":"2012","unstructured":"Obaya AJ, Rua S, Moncada-Pazos A, et al. The dual role of fibulins in tumorigenesis. Cancer Lett. 2012;325(2):132\u20138.","journal-title":"Cancer Lett"},{"issue":"8","key":"4063_CR44","doi-asserted-by":"crossref","first-page":"e70511","DOI":"10.1371\/journal.pone.0070511","volume":"8","author":"R Luo","year":"2013","unstructured":"Luo R, Zhang M, Liu L, et al. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One. 2013;8(8):e70511.","journal-title":"PLoS One"},{"issue":"4","key":"4063_CR45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.2776","volume":"222","author":"CF Hwang","year":"2010","unstructured":"Hwang CF, Chien CY, Huang SC, et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol. 2010;222(4):367\u201379.","journal-title":"J Pathol"},{"issue":"1","key":"4063_CR46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2010.11.004","volume":"121","author":"EL Song","year":"2011","unstructured":"Song EL, Hou YP, Yu SP, et al. EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol. 2011;121(1):174\u201380.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"4063_CR47","doi-asserted-by":"crossref","first-page":"e78783","DOI":"10.1371\/journal.pone.0078783","volume":"8","author":"J Chen","year":"2013","unstructured":"Chen J, Wei D, Zhao Y, et al. Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma. PLoS One. 2013;8(11):e78783.","journal-title":"PLoS One"},{"issue":"5","key":"4063_CR48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4149\/neo_2011_05_441","volume":"58","author":"JD Tong","year":"2011","unstructured":"Tong JD, Jiao NL, Wang YX, et al. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma. 2011;58(5):441\u20138.","journal-title":"Neoplasma"},{"issue":"15","key":"4063_CR49","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","volume":"367","author":"HI Pass","year":"2012","unstructured":"Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"4063_CR50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMc1213514","volume":"368","author":"K Hollevoet","year":"2013","unstructured":"Hollevoet K, Sharon E. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med. 2013;368(2):189.","journal-title":"N Engl J Med"},{"issue":"2","key":"4063_CR51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMc1213514","volume":"368","author":"K Lamote","year":"2013","unstructured":"Lamote K, Baas P, van Meerbeeck JP. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med. 2013;368(2):189\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"4063_CR52","first-page":"190","volume":"368","author":"HI Pass","year":"2013","unstructured":"Pass HI, Goparaju C. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med. 2013;368(2):190.","journal-title":"N Engl J Med"},{"issue":"6","key":"4063_CR53","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000321370","volume":"80","author":"AC Tanrikulu","year":"2010","unstructured":"Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010;80(6):480\u20137.","journal-title":"Respiration"},{"issue":"2","key":"4063_CR54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1165\/rcmb.2005-0130OC","volume":"34","author":"GT Stathopoulos","year":"2006","unstructured":"Stathopoulos GT, Zhu Z, Everhart MB, et al. Nuclear factor-\u03baB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol. 2006;34(2):142\u201350.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"4063_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.gene.2012.12.075","volume":"517","author":"R Jagirdar","year":"2013","unstructured":"Jagirdar R, Solenov EI, Hatzoglou C, et al. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma. Gene. 2013;517(1):99\u2013105.","journal-title":"Gene"},{"issue":"6","key":"4063_CR56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3892\/mco.2013.165","volume":"1","author":"T Yoshida","year":"2013","unstructured":"Yoshida T, Hojo S, Sekine S, et al. Expression of aquaporin-1 is a poor prognostic factor for stage II and III colon cancer. Mol Clin Oncol. 2013;1(6):953\u20138.","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"4063_CR57","first-page":"609","volume":"33","author":"N Hindy El","year":"2013","unstructured":"El Hindy N, Bankfalvi A, Herring A, et al. Correlation of aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma. Anticancer Res. 2013;33(2):609\u201313.","journal-title":"Anticancer Res"},{"issue":"2","key":"4063_CR58","doi-asserted-by":"crossref","first-page":"e98576","DOI":"10.1371\/journal.pone.0098576","volume":"9","author":"R Chen","year":"2014","unstructured":"Chen R, Shi Y, Amiduo R, et al. Expression and prognostic value of aquaporin 1, 3 in cervical carcinoma in women of Uygur ethnicity from Xinjiang, China. PloS One. 2014;9(2):e98576.","journal-title":"PloS One"},{"issue":"3","key":"4063_CR59","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1096\/fj.13-245621","volume":"28","author":"C Esteva-Font","year":"2014","unstructured":"Esteva-Font C, Jin BJ, Verkman AS. Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice. FASEB J. 2014;28(3):1446\u201353.","journal-title":"FASEB J"},{"issue":"4","key":"4063_CR60","first-page":"451","volume":"26","author":"JL L\u00f3pez-Campos","year":"2011","unstructured":"L\u00f3pez-Campos JL, S\u00e1nchez Silva R, G\u00f3mez Izquierdo L, et al. Overexpression of Aquaporin-1 in lung adenocarcinomas and pleural mesotheliomas. Histol Histopathol. 2011;26(4):451\u20139.","journal-title":"Histol Histopathol"},{"issue":"11","key":"4063_CR61","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/cncr.26497","volume":"118","author":"SC Kao","year":"2012","unstructured":"Kao SC, Armstrong N, Condon B, et al. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer. 2012;118(11):2952\u201361.","journal-title":"Cancer"},{"issue":"2","key":"4063_CR62","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/or.2014.3272","volume":"32","author":"V Richard","year":"2014","unstructured":"Richard V, Kindt N, Decaestecker C, et al. Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer. Oncol Rep. 2014;32(2):523\u20139.","journal-title":"Oncol Rep"},{"issue":"2","key":"4063_CR63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.urolonc.2012.09.013","volume":"32","author":"SQ Ji","year":"2014","unstructured":"Ji SQ, Su XL, Cheng WL, et al. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1a pathway. Urol Oncol. 2014;32(2):153\u201361.","journal-title":"Urol Oncol"},{"issue":"26","key":"4063_CR64","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.3748\/wjg.v16.i26.3258","volume":"16","author":"N Maharshak","year":"2010","unstructured":"Maharshak N, Cohen S, Lantner F, et al. CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol. 2010;16(26):3258\u201366.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"4063_CR65","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/IGC.0b013e31821c45b7","volume":"21","author":"RJ Cheng","year":"2011","unstructured":"Cheng RJ, Deng WG, Niu CB, et al. Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Intl J Gynecol Cancer. 2011;21(6):1004\u201312.","journal-title":"Intl J Gynecol Cancer"},{"issue":"6","key":"4063_CR66","doi-asserted-by":"crossref","first-page":"e98656","DOI":"10.1371\/journal.pone.0098656","volume":"9","author":"KT Morris","year":"2014","unstructured":"Morris KT, Nofchissey RA, Pinchuk IV, et al. Chronic macrophage migration inhibitory factor exposure induces mesenchymal epithelial transition and promotes gastric and colon cancers. PLoS One. 2014;9(6):e98656.","journal-title":"PLoS One"},{"issue":"8","key":"4063_CR67","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/bjc.2014.117","volume":"110","author":"C Otterstrom","year":"2014","unstructured":"Otterstrom C, Soltermann A, Opitz I, et al. CD74: a new prognostic factor for patients with malignant pleural mesothelioma. Br J Cancer. 2014;110(8):2040\u20136.","journal-title":"Br J Cancer"},{"issue":"11","key":"4063_CR68","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/onc.2012.143","volume":"32","author":"W Du","year":"2013","unstructured":"Du W, Wright BM, Li X, et al. Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene. 2013;32(11):1469\u201374.","journal-title":"Oncogene"},{"issue":"45","key":"4063_CR69","doi-asserted-by":"crossref","first-page":"37917","DOI":"10.1074\/jbc.M112.378299","volume":"287","author":"SE Brock","year":"2012","unstructured":"Brock SE, Rendon BE, Yaddanapudi K, et al. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J Biol Chem. 2012;287(45):37917\u201325.","journal-title":"J Biol Chem"},{"issue":"1","key":"4063_CR70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1499-3872(14)60011-4","volume":"13","author":"JF Zhang","year":"2014","unstructured":"Zhang JF, Hua R, Liu DJ, et al. Effect of CD74 on the prognosis of patients with resectable pancreatic cancer. Hepatobil Pancreat Dis Int. 2014;13(1):81\u20136.","journal-title":"Hepatobil Pancreat Dis Int"},{"issue":"5","key":"4063_CR71","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cellsig.2005.06.013","volume":"18","author":"H Lue","year":"2006","unstructured":"Lue H, Kapurniotu A, Fingerle-Rowson G, et al. Rapid andtransient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1\/CSN5 and Src kinase activity. Cell Signal. 2006;18(5):688\u2013703.","journal-title":"Cell Signal"},{"issue":"11","key":"4063_CR72","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","volume":"197","author":"L Leng","year":"2003","unstructured":"Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Expl Med. 2003;197(11):1467\u201376.","journal-title":"J Expl Med"},{"issue":"4","key":"4063_CR73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.immuni.2006.08.020","volume":"25","author":"X Shi","year":"2006","unstructured":"Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25(4):595\u2013606.","journal-title":"Immunity"},{"issue":"5","key":"4063_CR74","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/jcb.24027","volume":"113","author":"CY Lee","year":"2012","unstructured":"Lee CY, Su MJ, Huang CY, et al. Macrophage migration inhibitory factor increases cell motility and up\u2010regulates \u03b1v\u03b23 integrin in human chondrosarcoma cells. J Cell Biochem. 2012;113(5):1590\u20138.","journal-title":"J Cell Biochem"},{"issue":"42","key":"4063_CR75","doi-asserted-by":"crossref","first-page":"17444","DOI":"10.1073\/pnas.1107023108","volume":"108","author":"D Heinrichs","year":"2011","unstructured":"Heinrichs D, Knauel M, Offermanns C, et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A. 2011;108(42):17444\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4063_CR76","doi-asserted-by":"crossref","first-page":"e33402","DOI":"10.1371\/journal.pone.0033402","volume":"7","author":"T Iwata","year":"2012","unstructured":"Iwata T, Taniguchi H, Kuwajima M, et al. The action of D-dopachrome tautomerase as an adipokine in adipocyte lipid metabolism. PLoS One. 2012;7(3):e33402.","journal-title":"PLoS One"},{"issue":"4","key":"4063_CR77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bbrc.2012.08.091","volume":"426","author":"JJ Park","year":"2012","unstructured":"Park JJ, Seo SM, Kim EJ, et al. Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin \u03b21 signaling. Biochem Biophys Res Commun. 2012;426(4):461\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"4063_CR78","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cellsig.2012.12.020","volume":"25","author":"HW Chang","year":"2013","unstructured":"Chang HW, Lee YS, Nam HY, et al. Knockdown of beta-catenin controls both apoptotic and autophagic cell death through LKB1\/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal. 2013;25(4):839\u201347.","journal-title":"Cell Signal"},{"issue":"7","key":"4063_CR79","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/carcin\/bgt081","volume":"34","author":"M Kaur","year":"2013","unstructured":"Kaur M, Deep G, Jain AK, et al. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis. 2013;34(7):1585\u201392.","journal-title":"Carcinogenesis"},{"issue":"11","key":"4063_CR80","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/j.1349-7006.2009.01284.x","volume":"100","author":"H Miyoshi","year":"2009","unstructured":"Miyoshi H, Deguchi A, Nakau M, et al. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1\u00fe+\/\u2212 mice. Cancer Sci. 2009;100(11):2046\u201353.","journal-title":"Cancer Sci"},{"issue":"28","key":"4063_CR81","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010;107(28):12611\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4063_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.0306164","volume":"81","author":"ME Bianchi","year":"2007","unstructured":"Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1\u20135.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"4063_CR83","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012;18(3):598\u2013604.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4063_CR84","first-page":"173","volume":"25","author":"Y Wang","year":"2004","unstructured":"Wang Y, Faux SP, Hallden G, et al. Interleukin-1 beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol. 2004;25(1):173\u20138.","journal-title":"Int J Oncol"},{"issue":"13","key":"4063_CR85","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","volume":"72","author":"S Jube","year":"2012","unstructured":"Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290\u2013301.","journal-title":"Cancer Res"},{"issue":"5","key":"4063_CR86","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","volume":"183","author":"F Qi","year":"2013","unstructured":"Qi F, Okimoto G, Jube S, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling. Am J Pathol. 2013;183(5):1654\u201366.","journal-title":"Am J Pathol"},{"key":"4063_CR87","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","volume":"13","author":"C Tabata","year":"2013","unstructured":"Tabata C, Shibata E, Tabata R, et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer. 2013;13:205.","journal-title":"BMC Cancer"},{"issue":"8","key":"4063_CR88","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/MCG.0b013e318297fa65","volume":"47","author":"C Tabata","year":"2013","unstructured":"Tabata C, Kanemura S, Tabata R, et al. Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol. 2013;47(8):684\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"4063_CR89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cca.2014.04.027","volume":"436","author":"S Aggarwal","year":"2014","unstructured":"Aggarwal S, Devaraja K, Sharma SC, et al. Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance. Clin Chim Acta. 2014;436:35\u201340.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"4063_CR90","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1084\/jem.20111497","volume":"209","author":"W Hansen","year":"2012","unstructured":"Hansen W, Hutzler M, Abel S, et al. Neuropilin 1 deficiency on CD4+ Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012;209(11):2001\u201316.","journal-title":"J Exp Med"},{"issue":"4","key":"4063_CR91","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","volume":"193","author":"L Strizzi","year":"2001","unstructured":"Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193(4):468\u201375.","journal-title":"J Pathol"},{"issue":"19","key":"4063_CR92","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","volume":"13","author":"Q Li","year":"2007","unstructured":"Li Q, Yano S, Ogino H, et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 2007;13(19):5918\u201325.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4063_CR93","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1510\/icvts.2010.250357","volume":"12","author":"A Fiorelli","year":"2011","unstructured":"Fiorelli A, Vicidomini G, Di Domenico M, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg. 2011;12(3):420\u20134.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"4063_CR94","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4049\/jimmunol.179.1.708","volume":"179","author":"C Tabata","year":"2007","unstructured":"Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol. 2007;179(1):708\u201314.","journal-title":"J Immunol"},{"issue":"1","key":"4063_CR95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","volume":"189","author":"S Kumar-Singh","year":"1999","unstructured":"Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189(1):72\u20138.","journal-title":"J Pathol"},{"issue":"5","key":"4063_CR96","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","volume":"128","author":"F Demirag","year":"2005","unstructured":"Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005;128(5):3382\u20137.","journal-title":"Chest"},{"issue":"6C","key":"4063_CR97","first-page":"4833","volume":"26","author":"K Aoe","year":"2006","unstructured":"Aoe K, Hiraki A, Tanaka T, et al. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res. 2006;26(6C):4833\u20136.","journal-title":"Anticancer Res"},{"issue":"4","key":"4063_CR98","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","volume":"5","author":"A Yasumitsu","year":"2010","unstructured":"Yasumitsu A, Tabata C, Tabata R, et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5(4):479\u201383.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4063_CR99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","volume":"105","author":"N Hirayama","year":"2011","unstructured":"Hirayama N, Tabata C, Tabata R, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med. 2011;105(1):137\u201342.","journal-title":"Respir Med"},{"key":"4063_CR100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","volume":"34","author":"L Stayner","year":"2013","unstructured":"Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34:205\u201316.","journal-title":"Annu Rev Public Health"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-4063-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4063-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:26:59Z","timestamp":1718072819000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-4063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["4063"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-4063-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]}}}